OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 114 filers reported holding OCULAR THERAPEUTIX INC in Q3 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $378,562 | +55.3% | 120,561 | +155.2% | 0.00% | – |
| Q2 2023 | $243,743 | -5.7% | 47,237 | -3.7% | 0.00% | – |
| Q1 2023 | $258,530 | +139.2% | 49,057 | +27.5% | 0.00% | – |
| Q4 2022 | $108,101 | -54.6% | 38,470 | -33.0% | 0.00% | – |
| Q3 2022 | $238,000 | +14.4% | 57,425 | +11.1% | 0.00% | – |
| Q2 2022 | $208,000 | -22.4% | 51,677 | -4.5% | 0.00% | – |
| Q1 2022 | $268,000 | -28.5% | 54,099 | +0.5% | 0.00% | – |
| Q4 2021 | $375,000 | -60.0% | 53,853 | -42.6% | 0.00% | -100.0% |
| Q3 2021 | $938,000 | +3.4% | 93,751 | +46.6% | 0.00% | 0.0% |
| Q2 2021 | $907,000 | -7.4% | 63,933 | +7.2% | 0.00% | 0.0% |
| Q1 2021 | $979,000 | -18.6% | 59,654 | +2.8% | 0.00% | 0.0% |
| Q4 2020 | $1,202,000 | +69.1% | 58,044 | -37.8% | 0.00% | 0.0% |
| Q3 2020 | $711,000 | -5.7% | 93,385 | +3.2% | 0.00% | 0.0% |
| Q2 2020 | $754,000 | +139.4% | 90,530 | +42.2% | 0.00% | 0.0% |
| Q1 2020 | $315,000 | – | 63,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SUMMER ROAD LLC | 3,804,788 | $15,105,000 | 43.34% |
| Versant Venture Management, LLC | 2,215,384 | $8,795,074,000 | 2.90% |
| Opaleye Management Inc. | 1,900,000 | $7,543,000 | 2.09% |
| SV Health Investors, LLC | 628,236 | $2,494,000 | 1.46% |
| Endurant Capital Management LP | 716,124 | $2,843,000 | 1.12% |
| DELTEC ASSET MANAGEMENT LLC | 824,747 | $3,274,000 | 0.72% |
| NOTTINGHAM ADVISORS, INC. | 146,946 | $583,000 | 0.08% |
| Jump Trading, LLC | 39,255 | $156,000 | 0.05% |
| Man Group plc | 1,723,456 | $6,842,000 | 0.03% |
| JGP Global Gestao de Recursos Ltda. | 13,880 | $55,000 | 0.02% |